+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010624
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer immunotherapy drugs market stands at a critical inflection point, driven by continued advancements in immune-based oncology and evolving global healthcare dynamics. Senior leaders in biopharma, healthcare systems, and investment communities require actionable intelligence to harness new market potential and address operational complexities. This analysis provides a strategic overview tailored for executive decision-makers, capturing transformative trends, regulatory shifts, and the competitive environment.

Market Snapshot: Cancer Immunotherapy Drugs Market

The Cancer Immunotherapy Drugs Market grew from USD 243.31 billion in 2024 to USD 276.52 billion in 2025. It is expected to continue growing at a CAGR of 13.15%, reaching USD 510.62 billion by 2030.

Scope & Segmentation

This research applies an advanced segmentation framework to deliver detailed insights into the cancer immunotherapy market. The analysis spans therapeutic mechanisms, cancer types, care settings, and commercial channels across key global regions. Primary areas covered include:

  • Mechanisms of Action: Cancer vaccines, CAR T cell therapies, CTLA-4 inhibitors, cytokines, oncolytic viruses, PD-1 inhibitors, PD-L1 inhibitors
  • Cancer Types: Bladder cancer, hematologic malignancies (leukemia, lymphoma, multiple myeloma), kidney cancer, lung cancer (non-small cell and small cell), melanoma
  • Treatment Lines: First line, second line, third line and beyond
  • Routes of Administration: Intravenous, oral, subcutaneous
  • End Users: Ambulatory care centers, hospitals, specialty clinics
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific (including sub-regions such as the United States, Canada, China, India, Japan, and major economies in Europe, Middle East, Africa, and Asia-Pacific)
  • Key Companies: Merck & Co., Inc., Bristol-Myers Squibb Company, Roche Holding AG, AstraZeneca PLC, Novartis AG, Johnson & Johnson, Gilead Sciences, Inc., Amgen Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited

Cancer Immunotherapy Market: Key Takeaways

  • Immunotherapy is altering cancer care paradigms, moving beyond cytotoxic treatments to precision immune targeting across diverse tumors.
  • Growth is driven by innovative modalities—such as checkpoint inhibitors, cell-based therapies, and cancer vaccines—that improve survival in once intractable malignancies.
  • Multi-dimensional market segmentation highlights the importance of matching therapeutic mechanisms with cancer sub-types and patient profiles to maximize outcomes.
  • Industry competition centers on clinical differentiation, strategic licensing, and expanding access across established and emerging regions.
  • Service models are evolving as ambulatory centers and specialty clinics optimize administration and manage therapy-related adverse events.
  • Providers are strategically enhancing digital and real-world evidence capabilities to inform reimbursement, patient adherence, and treatment selection.

Tariff Impact: Navigating US Regulatory Changes in 2025

The 2025 changes to US tariffs on biologic drug imports introduce new operational risks and require manufacturers to adapt sourcing and distribution strategies. Cost volatility in raw materials and finished product pricing now influences reimbursement negotiations and access. Manufacturers are responding by diversifying supply chains and leveraging regional manufacturing to maintain market momentum. Regulatory flexibility, supply buffer strategies, and renegotiated contracts are being adopted by payers and providers to ensure stability and affordable care delivery.

Methodology & Data Sources

This market analysis leverages primary interviews with oncology leaders, regulatory experts, and supply chain executives, along with an extensive review of clinical literature, patent filings, and policy documents. Quantitative data are validated through triangulation across respected sources. Analytical frameworks such as PESTLE and Porter’s Five Forces support segmentation and competitive assessment, ensuring nuanced, data-backed recommendations.

Why This Report Matters

  • Offers executive leaders actionable insights on technology adoption, regional access strategies, and evolving regulatory frameworks in the cancer immunotherapy space.
  • Supports informed decision-making across product development, market expansion, and pricing optimization by highlighting real-world trends and key stakeholder perspectives.
  • Enables strategic resource allocation by providing clarity on segmentation, market drivers, and emerging business models.

Conclusion

The landscape of cancer immunotherapy is being shaped by rapid clinical innovation, regulatory evolution, and competitive repositioning. Stakeholders who leverage data-driven segmentation and regional insights will be best prepared to drive value and improve patient outcomes in this dynamic market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Immunotherapy Drugs Market, by Mechanism Of Action
8.1. Introduction
8.2. Cancer Vaccines
8.3. CAR T Cell Therapies
8.4. CTLA-4 Inhibitors
8.5. Cytokines
8.6. Oncolytic Viruses
8.7. PD-1 Inhibitors
8.8. PD-L1 Inhibitors
9. Cancer Immunotherapy Drugs Market, by Cancer Type
9.1. Introduction
9.2. Bladder Cancer
9.3. Hematologic Malignancies
9.3.1. Leukemia
9.3.2. Lymphoma
9.3.3. Multiple Myeloma
9.4. Kidney Cancer
9.5. Lung Cancer
9.5.1. Non-Small Cell Lung Cancer
9.5.2. Small Cell Lung Cancer
9.6. Melanoma
10. Cancer Immunotherapy Drugs Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Cancer Immunotherapy Drugs Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Cancer Immunotherapy Drugs Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Cancer Immunotherapy Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas Cancer Immunotherapy Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Cancer Immunotherapy Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Cancer Immunotherapy Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Bristol-Myers Squibb Company
17.3.3. Roche Holding AG
17.3.4. AstraZeneca PLC
17.3.5. Novartis AG
17.3.6. Johnson & Johnson
17.3.7. Gilead Sciences, Inc.
17.3.8. Amgen Inc.
17.3.9. Pfizer Inc.
17.3.10. Takeda Pharmaceutical Company Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CANCER IMMUNOTHERAPY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. CANCER IMMUNOTHERAPY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. CANCER IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CANCER IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR T CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 62. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 64. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 65. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 66. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 112. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 113. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 114. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 115. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 122. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 135. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 136. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 137. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 138. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 139. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 144. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 145. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 146. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 147. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 175. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 176. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 177. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 178. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 179. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 191. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 192. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 193. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 194. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 195. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 200. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 201. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 202. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 203. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 223. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 224. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 225. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 226. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 227. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 231. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 232. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 233. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 234. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 235. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 247. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 248. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 249. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 250. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 251. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 255. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 256. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 257. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 258. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 259. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 279. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 280. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 281. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 282. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 283. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 284. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 288. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 289. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 290. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 291. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 292. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 296. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 297. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 298. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 299. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 300. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA CANCER IMMUNOTHE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer Immunotherapy Drugs market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • AstraZeneca PLC
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 276.52 Billion
Forecasted Market Value ( USD ) by 2030 $ 510.62 Billion
Compound Annual Growth Rate13.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030 - Product Image

Immunotherapy Drugs Market by Therapy Type, Indication, Route of Administration, End User, Mechanism of Action - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Cancer Immunotherapy Market by Therapy Type, Indication, Mechanism Of Action, Line Of Therapy, Route Of Administration, End User - Global Forecast to 2030 - Product Image

Cancer Immunotherapy Market by Therapy Type, Indication, Mechanism Of Action, Line Of Therapy, Route Of Administration, End User - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Cancer Immunotherapy Market Size, Share & Trends Analysis Report by Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-use, with Growth Forecasts, 2025-2030 - Product Image

Cancer Immunotherapy Market Size, Share & Trends Analysis Report by Product, Application, Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-use, with Growth Forecasts, 2025-2030

  • Report
  • 110 Pages
  • Global
From
Immunotherapy Drugs - Global Strategic Business Report - Product Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030 - Product Image

Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.